PF-4136309, also known as INCB8761, is an orally available human chemokine receptor 2 (CCR2) antagonist with potential immunomodulating and antineoplastic activities. Upon oral administration, CCR2 antagonist PF-04136309 specifically binds to CCR2 and prevents binding of the endothelium-derived chemokine ligand CLL2 (monocyte chemoattractant protein-1 or MCP1) to its receptor CCR2, which may result in inhibition of CCR2 activation and signal transduction. This may inhibit inflammatory processes as well as angiogenesis, tumor cell migration, and tumor cell proliferation.
中文别名:
N-[2-[(3S)-3-[[4-羟基-4-[5-(嘧啶-2-基)吡啶-2-基]环己基]氨基]吡咯烷-1-基]-2-氧代乙基]-3-(三氟甲基)苯甲酰胺;